|
2024
|
Invention
|
Methods of treating malignant lymphoproliferative disorders.
Methods of treating malignant lymph... |
|
|
Invention
|
Treatment of pediatric cancers using gylcogen synthase kinase form b inhibitors. Methods of treat... |
|
2023
|
Invention
|
Oral dosage forms of elraglusib. The present invention relates to solid dispersions comprising am... |
|
2022
|
Invention
|
Methods of treating malignant lymphoproliferative disorders. Methods of treating malignant lympho... |
|
|
Invention
|
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2... |
|
2020
|
Invention
|
Compounds for the treatment of myelofibrosis.
The present invention provides methods of treating... |
|
|
Invention
|
Compounds for the treatment of myelofibrosis. The present invention provides methods of treating ... |
|
2019
|
Invention
|
Immunohistochemical staining for gsk-3.
Methods of using immunohistochemical staining to identif... |
|
|
Invention
|
Immunohistochemical staining for gsk-3. Methods of using immunohistochemical staining to identify... |
|
|
Invention
|
Methods of treating malignant lymphoproliferative disorders. Methods of treating malignant ly mph... |
|
|
Invention
|
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors. Pha... |
|
|
Invention
|
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors. ... |
|
2018
|
Invention
|
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,... |
|
2016
|
G/S
|
Biopharmaceutical research for development of targeted therapies for use in the treatment of carc... |
|
2015
|
G/S
|
Biopharmaceutical research and development; biopharmaceutical research for development of targete... |
